RVMD
Revolution Medicines, Inc.
NASDAQ · Healthcare · Biotechnology · US
$210.02
−0.40%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -81.3%
- EPS
- -96.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +7.5%
- EPS
- +11.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -85.1%
- EBIT
- -71.5%
- Net income
- -88.5%
- EPS
- -66.2%
- Free cash flow
- -60.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026